Corona Category

The Covid-19 cases are piling up once more, fueling fears a full-blown resurgence of the pandemic is in...

It looks like the pandemic isn’t behind us yet. The alarming rise in Covid-19 cases has coincided with...

If you had to choose an all-out success story of the Covid era, Moderna (MRNA) would be high...

The conversation might have turned from dealing with a pandemic to living in a post-covid climate – or...

Novavax (NVAX) had fallen behind in the race to get a Covid-19 vaccine to market and watched as...

Step by step, life is returning to pre-Covid-19 patterns. The resumption of travel, the economic reopening and return...

If you’re going to be late to the party, at least don’t fall flat on your face as...

One of the early frontrunners in the race to get a Covid-19 vaccine to market, Novavax (NVAX) has...

Getting a Covid-19 vaccine to market has proven to be an arduous task for Novavax (NVAX). As one...

If there was one coronavirus stock you wanted to back in 2020, it was Novavax (NVAX). The small...

Inovio Pharmaceuticals (INO) has been playing catch up in the Covid-19 vaccine race for a while now. One...

Moderna’s (MRNA) opportunity to halt the spread of Covid-19 made the biotech company one of 2020’s star performers....

Ocugen (OCGN) has been a 2021 success story, as the eye disease specialist has decided to moonlight in...

The developments are coming in thick and fast at Sorrento Therapeutics (SRNE). Recent times have seen a flurry...

As the saying goes, when life gives you lemons, make lemonade. Or as Ocugen (OCGN) has adapted the...

Several coronavirus stocks were on the move this week in reaction to the CDC (Centers for Disease Control...

By now you’ve heard the news. On Tuesday, April 13, the U.S. Centers for Disease Control and Food...

Despite year-to-date gains of 61%, shares of Novavax (NVAX) have retreated by 44% since the yearly highs of...

Moderna (MRNA) stock currently sits 30% below the yearly highs reached in early February. Jefferies analyst Michael Yee...

Friday was not a fun day to be invested in Co-Diagnostics (CODX). Shares of the Coronavirus test maker...

Once a specialist in oncology drugs and pain management, last year, Sorrento Therapeutics (SRNE) refocused its business on...

The stock market has been pulled aggressively in both directions in 2021, but the moves are relatively tame...

Ocugen (OCGN) is a latecomer to the coronavirus stock party. But in true latecomer fashion, it has made...

The available vaccines’ questionable effectiveness against mutant strains and the logistic challenges of worldwide distribution, suggest the battle...

Despite the reduction in global Covid-19 cases, and the anticipated gradual return to normalcy, the fear of mutant...

B. Riley analyst Mayank Mamtani has long banged the drum for Novavax (NVAX). The latest developments surrounding the...

Shares of vaccine researcher Inovio Pharmaceuticals (INO) are currently trading around the $15 level, and one analyst thinks...

What does it take to move a stock price from $0.29 to $15.81 — an increase of 5,350%...

The new coronavirus mutant strains are playing havoc with the already approved Covid-19 vaccines. The latest data shows...

Novavax (NVAX) was the coronavirus stock to hold last year, as the company punched far above its weight...

It’s official, a new Covid-19 vaccine candidate has entered the fray. On Tuesday, Ocugen (OCGN) announced it had...

Over the past week, investors optimistically pushed Vaxart’s (VXRT) share price up by over 100%. High short-interest and...

In the race to bring a coronavirus vaccine to market, Novavax (NVAX) looked like a loser — lagging...

Coronavirus stocks played a massive part in the stock market’s 2020 narrative. However, in 2021, so far, Moderna...

Some companies favor a “do one job and do it well” approach. However, that is not the Sorrento...

2020 introduced the term “coronavirus stocks.” These are the companies working on solutions to fend off the Covid-19...

Think coronavirus stocks are so 2020? Think again. Shares of Gritstone Oncology (GRTS) took off by a whooping...

Over the past 12 months, Moderna’s (MRNA) share price has increased by a spectacular 517%. Of course, the...

The major U.S. equity-indexes are hovering around all-time highs, and a question that frequently pops up these days,...

From a company barely known outside industry circles a year ago, Moderna (MRNA) has now become a household...

Coronavirus-focused stocks have been prone to surge majestically after the announcement of positive news. Last Friday, Applied DNA...

Inovio Pharmaceuticals’ (INO) 2020 was a tale of two contrasting halves. Shares skyrocketed during the first 6 months...

Arcturus Therapeutics (ARCT) investors felt the impact of a thunderous thud on Tuesday, following the share price’s collapse....

Returns wise, Novavax (NVAX) has undoubtedly been the most successful coronavirus stock of them all, with 2020 gains...

Last week, Moderna’s (MRNA) Covid-19 vaccine candidate mRNA-1273 became the second approved vaccine in the U.S. after it...

Hot on the heels of the FDA granting EUA (emergency use authorization) for Pfizer/BioNTech’s Covid-19 vaccine BNT162b2, last...

Last week, Moderna (MRNA) kicked off its TeenCOVE Study, dosing the first participants in the Phase 2/3 trial...

Covid-19 has been responsible for a complete shift in how society operates. On a lighter note, it has...

Moderna (MRNA) stock has been one of 2020’s star performers, up 695%, and judging by its real-world results,...

2020 has been some journey for Inovio Pharmaceuticals (INO). For this formerly little-known biotech, the narrative has swung...